Veloxis wins popularity among newly transplanted patients: "We're way ahead of what we had anticipated"

15.5 percent of all US kidney transplant patients now receive treatment with Veloxis' drug Envarsus to prevent organ rejection. This is far more than the company dared to hope for when the drug was approved for de novo patients in December.

Photo: Laurie Skrivan / AP / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles